The Saudi Vaccine and Biomanufacturing Center (SVBC), the first of its kind in the Middle East, broke ground at KAUST on December 15. The center will develop vaccines and biopharmaceutical products under good manufacturing practice (GMP) standards. It is a joint project championed by the Ministry of Energy, Industry and Mineral Resources through the Industrial Clusters Program and supported by KACST. Why it matters: The center will serve as a national platform for pharmaceutical innovation and address epidemic risks in the Kingdom, such as MERS-CoV.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
The provided content mentions KAUST (King Abdullah University of Science and Technology) and its association with King Abdullah bin Abdulaziz Al Saud. It also includes a copyright notice. Why it matters: This is a routine update reflecting KAUST's branding and legal information.
KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.
MBZUAI is hosting a free webinar on August 4th from 6-7pm titled ‘How does AI help fight the COVID-19 pandemic?’. The webinar will be led by Dr. Mohammad Yaqub, Assistant Professor at MBZUAI, and will discuss the role of AI before, during, and after a pandemic. Registration is available at www.mbzuai.ac.ae/aitalks. Why it matters: This webinar aims to educate the public on the potential of AI in addressing pandemics, aligning with MBZUAI's social responsibility efforts in the UAE.
Dr. Mohammad Yaqub from MBZUAI will present AI solutions used to combat the COVID-19 pandemic, addressing healthcare consequences, social, economic, and policy-making decisions. The talk will cover the applications of AI and also discuss challenges like privacy, data needs, generalizability, data noise, and human acceptance. Yaqub's background includes a DPhil from the University of Oxford in Biomedical Engineering and research at the Institute of Biomedical Engineering, focusing on machine learning solutions for medical problems. Why it matters: This talk highlights the important role of AI in addressing pandemics and the ethical considerations that come with its application in healthcare and policymaking.
KAUST researchers are analyzing the SARS-CoV-2 genome to identify potential targets for treatment and vaccine development. They are using the KAUST Metagenome Analysis Platform (KMAP) and the university's supercomputer to compare and analyze genomic data. The research focuses on identifying key genes for detection and treatment of COVID-19. Why it matters: This research contributes to the global effort to combat the pandemic and highlights KAUST's capabilities in genomic data analysis and computational bioscience.